222541-11-9

Basic information

• Product Name: ethyl (E)-<1-<4-(2-methylbenzoylamino)benzoyl>-2,3,4,5-tetrahydro-1H-1-benzoazepin-5-ylidene>acetate
• Synonyms: ethyl (E)-<1-<4-(2-methylbenzoylamino)benzoyl>-2,3,4,5-tetrahydro-1H-1-benzoazepin-5-ylidene>acetate
• CAS NO: 222541-11-9
• Molecular Weight: 468.552
• Mol File: 222541-11-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: ethyl (E)-<1-<4-(2-methylbenzoylamino)benzoyl>-2,3,4,5-tetrahydro-1H-1-benzoazepin-5-ylidene>acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl (E)-<1-<4-(2-methylbenzoylamino)benzoyl>-2,3,4,5-tetrahydro-1H-1-benzoazepin-5-ylidene>acetate(222541-11-9)
• EPA Substance Registry System: ethyl (E)-<1-<4-(2-methylbenzoylamino)benzoyl>-2,3,4,5-tetrahydro-1H-1-benzoazepin-5-ylidene>acetate(222541-11-9)

Safety Data

• Hazardous Substances Data: 222541-11-9(Hazardous Substances Data)

Upstream product

• 137976-09-1 1-(4-aminobenzoyl)-2,3,4,5-tetrahydro1H-1-benzazepin-5-one 
• 933-88-0 ortho-toluoyl chloride 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 137976-61-5 2-methyl-4'-[(5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanilide 

Downstream Products

• 222541-19-7 (E)-N-methyl-<1-<4-(2-methylbenzoylamino)benzoyl>-2,3,4,5-tetrahydro-1H-1-benzoazepin-5-ylidene>acetamide 
• 222541-18-6 ethyl <1-<4-(2-methylbenzoylamino)benzoyl>-2,3-dihydro-1H-1-benzoazepin-5-yl>acetate 
• 222541-29-9 ethyl <1-<4-(2-methylbenzoylamino)benzoyl>-2,3,4,5-tetrahydro-1H-1-benzoazepin-5-yl>acetate 

Relevant articles and documents

Nonpeptide arginine vasopressin antagonists for both V(1A) and V2 receptors: Synthesis and pharmacological properties of 4'-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl]benzanilide and 4'-[5-(substituted methyl)-2,3-dihydro-1H-1-benzoazepine-1- carbonyl]benzanilide derivatives

Arginine vasopressin (AVP) has a dual action, i.e. vasoconstriction and water reabsorption via V(1A) and V2 receptors, and may play a role in a number of diseases, including congestive heart failure (CHF), hypertension, renal disease, edema, and hyponatremia. We have attempted to develop a new series of AVP antagonists for both V(1A) and V2 receptors based on the hypothesis that the blockade of both V(1A) and V2 receptors might be beneficial to CHF patients. In this report, a series of compounds structurally related to 4'-[5-(substituted methylidene)2,3,4,5-tetrahydro- 1H-1-benzoazepine-1-carbonyl]benzanilide (exo-olefin isomer) and 4'-[5- (substituted methyl)2,3-dihydro-1H-1-benzoazepine-1-carbonyl]benzanilide (endo-olefin isomer) were synthesized and examined to have AVP antagonist activity for both V(1A) and V2 receptors. As a result, it was found that the (E)-exo-olefin isomers showed more potent binding affinity compared with endo-olefin isomers. Among these (E)-exo-olefin isomers, (E)-N-methyl-{1- [4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzoazepin-5- ylidene}ac-etamide (14) exhibited the most potent binding affinitiy and (E)- N-methyl-(1-{4-12-(4'methylphenyl)benzoyl-amino]benzoyl}-2,3,4,5- tetrahydro-1H-1-benzoazepin-5-ylidene)acetamide (20) exhibited a high AVP antagonist activity for both V(1A) and V2 receptors after intravenous administration. Details of the synthesis and pharmacological properties of this series are presented.